Gain Therapeutics, Inc. (GANX) has 10 open-market insider trades by 6 insiders since 2022. The most active filer is Eric I. Richman, Director.
| Name | Title | Tier | Trades | Value | Last Trade |
|---|---|---|---|---|---|
| Jeffrey Scott Riley | Dir | — | 1 | $116K | 2024-03-28 |
| Eric I. Richman | Dir | — | 3 | $64K | 2024-07-01 |
| Khalid Islam | Chairman | — | 1 | $50K | 2024-08-09 |
| Salvatore Calabrese | CFO | — | 2 | $16K | 2022-05-19 |
| Gene Mack | CFO and Interim CEO | — | 1 | $15K | 2024-08-09 |
| Matthias Alder | CEO | — | 2 | $5K | 2024-03-26 |
| Insider | Title | Type | Value | Date |
|---|---|---|---|---|
| Gene Mack | CFO and Interim CEO | Buy | $15K | 2024-08-09 |
| Khalid Islam | Chairman | Buy | $50K | 2024-08-09 |
| Eric I. Richman | Director | Buy | $21K | 2024-07-01 |
| Jeffrey Scott Riley | Director | Buy | $116K | 2024-03-28 |
| Matthias Alder | CEO | Sell | $507 | 2023-12-21 |
| Matthias Alder | CEO | Sell | $5K | 2023-12-07 |
Companies that share insiders with GANX, and sector peers with recent insider buying. Related by who files, not by how the stocks move.
| Eric I. Richman | CEO | Buy | $6K | 2022-05-25 |
| Salvatore Calabrese | CFO | Buy | — | 2022-05-19 |
| Eric I. Richman | CEO | Buy | $37K | 2022-05-19 |
| Salvatore Calabrese | CFO | Buy | $16K | 2022-05-19 |